Xeltis Secures €20.5 Million in Latest Funding Round
Xeltis, a healthcare company based in Eindhoven, The Netherlands, has successfully raised €20.5 million in a new funding round. The company is known for developing innovative implants that help the body naturally create living and durable vessels.
Investment Details
The latest funding round was led by Horizon 3 Healthcare, a new investor to Xeltis. Other participants included established investors such as the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, and DaVita.
Strategic Use of Funds
The newly acquired funds will be directed towards several key initiatives. Xeltis plans to use the capital to finalize the ongoing pivotal trial of their aXess™ program in the United States. This includes preparing for FDA submission and launching the product commercially in the U.S. Additionally, the funding will support the European commercial rollout of aXess™, enhance manufacturing capabilities, and advance other programs like XABG and XPAD in clinical settings.
Company Leadership and Vision
Co-Founder Martijn Cox has been instrumental in steering Xeltis towards its ambitious goals. "This funding enables us to continue our mission of transforming patient care through innovative medical solutions," Cox stated.
Expanding Healthcare Solutions
This latest investment marks a significant step for Xeltis as it aims to expand its reach and impact in the healthcare sector. By focusing on clinical, regulatory, and commercial execution, the company is poised to make substantial advancements in patient treatment options.
Xeltis continues to work on its pioneering technologies that could potentially revolutionize how certain medical conditions are treated, offering hope for improved outcomes in cardiovascular care.